interventional-cardiology
(12)
Selera Medical
Selera Medical is a Y Combinator-backed (W24) medical device startup building MILO - minimally invasive lymphatic offloading - a one-time, catheter-based procedure that treats fluid overload in chronic heart failure. Instead of a lifelong drug regimen, Selera taps the body's lymphatic system to drain trapped fluid from the interstitial space, aiming to break the cycle of repeat hospitalizations that defines late-stage heart failure. Founded in 2023 by CEO Stacie Arechavala and CTO Kevin Bui, both former Stanford Biodesign fellows.
Spectrumedics Medical
Spectrumedics Medical is a Singapore-based medical device company building active, minimally-invasive cardiovascular interventional systems. Its flagship product, the Sonico-CX intravascular lithotripsy (IVL) system, uses acoustic pressure waves to break up calcified coronary lesions so cardiologists can restore blood flow and place stents. In January 2026 the company earned an EU CE mark, joining Johnson & Johnson MedTech's Shockwave and Elixir Medical as one of the few companies with EU-approved coronary IVL systems. Backed by a Series A round led by Legend Capital, Spectrumedics operates from the JTC MedTech Hub and is commercializing across Asia Pacific and Latin America while expanding into Europe and the Middle East.
CardioRenal Systems, Inc.
CardioRenal Systems is a Milford, Massachusetts medical device company developing RenalPro (marketed as RenalGuard outside the US), an automated fluid-management system that prevents acute kidney injury in high-risk hospital settings. By monitoring urine output in real time and matching IV hydration in milliliter increments, the system keeps patients balanced during cardiac surgery, catheter procedures, and ICU care. RenalPro holds FDA Breakthrough Device Designation and a CE Mark, and in a 220-patient randomized UK trial cut AKI by 52% versus standard care.
Evident Vascular, Inc.
Evident Vascular is a San Jose-based medical device startup building an AI-powered intravascular ultrasound (IVUS) platform designed for peripheral vascular interventions. Founded in 2023 and led by CEO Howard Rosen, the company aims to fix the long-standing trade-off between image quality and clinical workflow that has limited IVUS adoption, targeting FDA 510(k) clearance ahead of a U.S. launch. It raised a $35M Series A from Vensana Capital and closed an undisclosed Series B in 2025.
EchoPixel, Inc.
EchoPixel is a Silicon Valley medical visualization company that turns ordinary CT, MRI and ultrasound scans into life-size, interactive 4D holograms of a patient's own anatomy. Its FDA-cleared True3D platform and Holographic Therapy Guidance (HTG) let surgeons and interventional cardiologists reach in and manipulate a digital twin of a heart or organ - no headset or glasses required - to plan and guide complex, minimally invasive procedures.
Elixir Medical Corporation
Elixir Medical Corporation is a privately held Milpitas, California medical device company building implantable technologies to treat coronary and peripheral artery disease. Its flagship DynamX Coronary Bioadaptor is a metal implant with a resorbable polymer coating that dissolves over roughly six months, 'uncaging' the artery so the vessel can pulse and move naturally rather than remaining permanently rigid like a conventional stent. Founded in 2005 by Motasim Sirhan, Elixir has produced a lineage of coronary devices - the DESolve bioresorbable scaffold, the DESyne family of drug-eluting stents, the LithiX intravascular lithotripsy system, and the DynamX bioadaptor - and has reported two consecutive randomized trials showing reduced long-term cardiac event rates versus current drug-eluting stents.
Revamp Medical
Revamp Medical is an Israeli medical device company building the Doraya catheter, a temporary, adjustable flow-reducing catheter for patients hospitalized with acute heart failure. Deployed in the infrarenal inferior vena cava for up to 12 hours, Doraya is designed to relieve venous congestion and improve response to diuretic therapy in patients who respond poorly to standard drugs - addressing the local mechanism of diuretic resistance rather than relying on systemic drugs or dialysis. Founded in 2016 and based in Netanya, the company won FDA Breakthrough Device designation in 2020 and closed a KCK Medtech-led Series A in 2023 to fund U.S. clinical trials.
Supira Medical
Supira Medical is a clinical-stage cardiovascular device company in Los Gatos, California, building a next-generation percutaneous ventricular assist device (pVAD). Incubated inside Amr Salahieh's Shifamed innovation hub and led by CEO Nitin Salunke, the Supira System is a low-profile (10F), high-flow heart pump designed to give the heart temporary circulatory support during high-risk coronary interventions and cardiogenic shock, with the goal of moving more blood through a smaller sheath than the incumbent devices. The company raised a $120M oversubscribed Series E in March 2025 and won FDA approval to begin its SUPPORT II pivotal trial in 2026.
AngioWave Imaging
AngioWave Imaging is a Massachusetts-based medical AI company building post-processing software that sharpens fluoroscopic angiograms in the cardiac catheterization lab. Its FDA 510(k)-cleared AngioWaveNet uses a spatiotemporal, convolutional deep neural network (branded STEP) to reveal blood-vessel detail that is hard to see on the raw angiogram, helping interventional cardiologists diagnose and treat coronary artery disease. The software runs on top of any existing fluoroscopy system, requiring no new hardware.
Intravascular Imaging Incorporated (i3)
Intravascular Imaging Incorporated (i3) is a Wilton, Connecticut medical device company building a next-generation coronary imaging catheter. Its 3-French NIRF-IVUS catheter fuses intravascular ultrasound (IVUS), the clinical standard for guiding stent placement, with near-infrared fluorescence (NIRF) molecular imaging in a single device. The combination lets cardiologists see not just the anatomy of a coronary artery but the biology inside it - plaque inflammation, arterial dissections, transplant vasculopathy, and fibrin in unhealed stents. Spun out of work at Massachusetts General Hospital/Harvard Medical School and the Technical University of Munich, i3 aims to upgrade percutaneous coronary intervention (PCI) by helping doctors look beyond anatomy.
R. Scott Jones
R. Scott Jones is the Chairman and CEO of Intravascular Imaging Incorporated (i3), a Wilton, Connecticut medtech startup commercializing a 3-French NIRF-IVUS catheter that lets cardiologists see both the anatomy and the biology of a diseased coronary artery in a single pass. A medical device operator with more than 25 years in the field, he once ran GE Medical Systems' cardiovascular business across the Americas and Asia and has steered companies from two-person startups to organizations of 7,000 employees. At i3 he is the commercial engine behind a technology born in the labs of Massachusetts General Hospital and the Technical University of Munich.
Robert Weigle
Robert K. Weigle is a medical device and diagnostics executive with more than 25 years of experience taking healthcare products from pre-clinical research to commercial launch. He is CEO of NOW Diagnostics, an independent board member of Tenon Medical, and a former entrepreneur-in-residence at DigitalDx Ventures. He led Benvenue Medical as CEO for over a decade, raising more than $200 million and launching spine devices in two markets, and later ran saliva-based diagnostics companies focused on cancer detection. His career spans Fortune 500 names like Johnson & Johnson and Baxter as well as a string of venture-backed startups.